Search results for "61"

showing 10 items of 3634 documents

Decreased Fibrogenesis After Treatment with Pirfenidone in a Newly Developed Mouse Model of Intestinal Fibrosis

2016

BACKGROUND Fibrosis as a common problem in patients with Crohn's disease is a result of an imbalance toward excessive tissue repair. At present, there is no specific treatment option. Pirfenidone is approved for the treatment of idiopathic pulmonary fibrosis with both antifibrotic and anti-inflammatory effects. We subsequently investigated the impact of pirfenidone treatment on development of fibrosis in a new mouse model of intestinal fibrosis. METHODS Small bowel resections from donor mice were transplanted subcutaneously into the neck of recipients. Animals received either pirfenidone (100 mg/kg, three times daily, orally) or vehicle. RESULTS After administration of pirfenidone, a signif…

0301 basic medicinemedicine.medical_specialtyPyridonesBlotting Western610 Medicine & healthGastroenterologyImmunoenzyme TechniquesMice03 medical and health sciencesIdiopathic pulmonary fibrosis0302 clinical medicineTransforming Growth Factor betaFibrosis10049 Institute of Pathology and Molecular PathologyInternal medicinemedicineAnimalsImmunology and Allergy2715 GastroenterologyCell ProliferationMice Inbred BALB CbiologyCell growthbusiness.industryAnti-Inflammatory Agents Non-SteroidalGastroenterologyPirfenidoneTransforming growth factor betamedicine.diseaseFibrosisMice Inbred C57BLTransplantationBlotDisease Models AnimalIntestinal Diseases10219 Clinic for Gastroenterology and Hepatology030104 developmental biology2723 Immunology and Allergybiology.proteinFemale030211 gastroenterology & hepatologyCollagen10069 Clinic of Cranio-Maxillofacial SurgerybusinessAfter treatmentmedicine.drugInflammatory Bowel Diseases
researchProduct

The Overlapping Area of Non-Celiac Gluten Sensitivity (NCGS) and Wheat-Sensitive Irritable Bowel Syndrome (IBS): An Update

2017

Gluten-related disorders have recently been reclassified with an emerging scientific literature supporting the concept of non-celiac gluten sensitivity (NCGS). New research has specifically addressed prevalence, immune mechanisms, the recognition of non-immunoglobulin E (non-IgE) wheat allergy and overlap of NCGS with irritable bowel syndrome (IBS)-type symptoms. This review article will provide clinicians with an update that directly impacts on the management of a subgroup of their IBS patients whose symptoms are triggered by wheat ingestion.

0301 basic medicinemedicine.medical_specialtySettore MED/09 - Medicina InternaGlutensamylase-trypsin inhibitors (ATIs)Gluten sensitivitylcsh:TX341-641Non-Celiac Gluten SensitivityReviewWheat HypersensitivityGastroenterologyIrritable Bowel Syndrome03 medical and health sciencesDiet Gluten-Free0302 clinical medicineMalabsorption Syndromesgluten-free dietMedizinische FakultätInternal medicineMedicineHumansddc:610Irritable bowel syndromeImmune mechanismsRandomized Controlled Trials as Topicgluten-related disorder030109 nutrition & dieteticsNutrition and Dieteticsbusiness.industrygluten sensitivitynutritional and metabolic diseasesGluten-related disordersWheat-Sensitive Irritable Bowel Syndromemedicine.diseaseMalabsorption Syndromedigestive system diseasesNon-Celiac Gluten Sensitivity; Wheat-Sensitive Irritable Bowel SyndromeReview articlewheat allergy030211 gastroenterology & hepatologybusinessNon-celiac gluten sensitivitygluten-related disorderslcsh:Nutrition. Foods and food supplyWheat allergyGlutenceliac diseaseFood ScienceHuman
researchProduct

Association of statin use and clinical outcomes in heart failure patients : a systematic review and meta-analysis

2019

Abstract Background The role of statins in patients with heart failure (HF) of different levels of left ventricular ejection fraction (LVEF) remains unclear especially in the light of the absence of prospective data from randomized controlled trials (RCTs) in non-ischemic HF, and taking into account potential statins’ prosarcopenic effects. We assessed the association of statin use with clinical outcomes in patients with HF. Methods We searched PubMed, EMBASE, Scopus, Google Scholar and Cochrane Central until August 2018 for RCTs and prospective cohorts comparing clinical outcomes with statin vs non-statin use in patients with HF at different LVEF levels. We followed the guidelines of the 2…

0301 basic medicinemedicine.medical_specialtyStatinmedicine.drug_classEndocrinology Diabetes and MetabolismClinical Biochemistry610Heart failure030204 cardiovascular system & hematologyLower risklaw.invention03 medical and health sciences0302 clinical medicineEndocrinologyRandomized controlled trialHeart failure; Hospitalization; Meta-analysis; Mortality; StatinslawInternal medicineHumansMedicineCardiac and Cardiovascular SystemsProspective StudiesMortalitylcsh:RC620-627Kardiologibusiness.industryResearchBiochemistry (medical)Hazard ratioStatinsmedicine.diseaseConfidence interval3. Good healthHospitalizationlcsh:Nutritional diseases. Deficiency diseasesMeta-analysisTreatment Outcome030104 developmental biologyMeta-analysisHeart failureHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessCohort study
researchProduct

Filifactor alocis and Tumor Necrosis Factor-Alpha Stimulate Synthesis of Visfatin by Human Macrophages

2021

There is little known about the effect of the periodontopathogen Filifactor alocis on macrophages as key cells of the innate immune defense in the periodontium. Therefore, the aim of the present study was to investigate the effect of F. alocis and additionally of the pro-inflammatory cytokine tumor necrosis factor-alpha (TNF&alpha

0301 basic medicinemedicine.medical_treatmentCD14tumor necrosis factor<i>Filifactor alocis</i>610 Medicine & healthmacrophageArticleCatalysisProinflammatory cytokineInorganic Chemistrylcsh:Chemistry03 medical and health sciences0302 clinical medicinestomatognathic systemvisfatinmedicineMacrophagePhysical and Theoretical Chemistry610 Medicine &amp; healthMolecular Biologyperiodontitislcsh:QH301-705.5SpectroscopyPeriodontitisInnate immune systembusiness.industryOrganic Chemistry030206 dentistryGeneral Medicinemedicine.diseaseComputer Science ApplicationsFilifactor alocisTLR2030104 developmental biologyCytokinelcsh:Biology (General)lcsh:QD1-999ImmunologyTumor necrosis factor alphaMMP1businessCOX2International Journal of Molecular Sciences
researchProduct

Tissue microenvironment dictates the fate and tumor-suppressive function of type 3 ILCs

2017

Nussbaum et al. found that tumor suppression through innate lymphoid cells (ILCs) cannot be predicted solely based on the ILC phenotype and lineage but that their immune properties are shaped both by their ontogeny and by the tissue microenvironment they reside in.

0301 basic medicinemedicine.medical_treatmentImmunology314610 Medicine & healthBiology10263 Institute of Experimental ImmunologyArticle31103 medical and health sciencesMiceRAR-related orphan receptor gammaCell Line TumormedicineImmunology and AllergyAnimalsLymphocytesskin and connective tissue diseasesTranscription factorResearch ArticlesMice Knockout2403 ImmunologyInnate lymphoid cellNeoplasms ExperimentalNuclear Receptor Subfamily 1 Group F Member 3PhenotypeCell biologybody regionsKiller Cells NaturalMice Inbred C57BL030104 developmental biologyCytokineCellular MicroenvironmentCell cultureTumor progressionInterleukin 122723 Immunology and AllergyCytokines570 Life sciences; biologyTranscription Factors
researchProduct

Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine?

2021

Gastroenteropancreatic neuroendocrine neoplasia (GEPNEN) comprises clinically as well as prognostically diverse tumour entities often diagnosed at late stage. Current classification provides a uniform terminology and a Ki67-based grading system, thereby facilitating management. Advances in the study of genomic and epigenetic landscapes have amplified knowledge of tumour biology and enhanced identification of prognostic and potentially predictive treatment subgroups. Translation of this genomic and mechanistic biology into advanced GEPNEN management is limited. ‘Targeted’ treatments such as somatostatin analogues, peptide receptor radiotherapy, tyrosine kinase inhibitors and mammalian target…

0301 basic medicinemedicine.medical_treatmentcancer geneticsNeuroendocrine tumorsBioinformaticschemotherapyMolecular oncologyEpigenesis Genetic03 medical and health sciences0302 clinical medicinemolecular oncologyStomach NeoplasmsIntestinal NeoplasmsBiomarkers TumormedicineHumanscancer genetics; chemotherapy; immunotherapy; molecular oncology; neuroendocrine tumorsEpigeneticsPrecision Medicine610 Medicine &amp; healthbusiness.industryGastroenterologyImmunotherapymedicine.diseasePancreatic NeoplasmsRadiation therapyClinical trial030104 developmental biologyTargeted drug delivery030220 oncology & carcinogenesis570 Life sciences; biologyIdentification (biology)immunotherapyneuroendocrine tumorsbusiness
researchProduct

EV-TRACK: transparent reporting and centralizing knowledge in extracellular vesicle research

2017

We argue that the field of extracellular vesicle (EV) biology needs more transparent reporting to facilitate interpretation and replication of experiments. To achieve this, we describe EV-TRACK, a crowdsourcing knowledgebase (http://evtrack.org) that centralizes EV biology and methodology with the goal of stimulating authors, reviewers, editors and funders to put experimental guidelines into practice.

0301 basic medicineminimum informationblood-plasmaphysiology [Extracellular Vesicles]Biomedical ResearchInternationalityComputer sciencephenotype[SDV]Life Sciences [q-bio]MedizinexosomesCrowdsourcingBioinformaticsBiochemistry03 medical and health sciencesExtracellular VesiclesultracentrifugationBiological propertycancerddc:610resolution flow-cytometryMolecular Biologysubpopulationsbusiness.industrybiological-propertiesCell BiologyExtracellular vesicleData scienceDatabases BibliographicReplication (computing)030104 developmental biologycellsbusinessBiotechnology
researchProduct

The MID1 protein is a central player during development and in disease.

2015

Loss-of-function mutations in the MID1 gene cause a rare monogenic disorder, Opitz BBB/G syndrome (OS), which is characterized by malformations of the ventral midline. The MID1 gene encodes the MID1 protein, which assembles a large microtubule-associated protein complex. Intensive research over the past several years has shed light on the function of the MID1 protein as a ubiquitin ligase and regulator of mTOR signalling and translational activator. As a central player in the cell MID1 has been implicated in the pathogenesis of various other disorders in addition to OS including cancer and neurodegenerative diseases. Influencing the activity of the MID1 protein complex is a promising new st…

0301 basic medicinephysiopathology [Huntington Disease]CarcinogenesisUbiquitin-Protein LigasesRegulatorDiseaseBiologyBioinformaticsmedicine.disease_causephysiopathology [Alzheimer Disease]Congenital AbnormalitiesPathogenesis03 medical and health sciencesMiceAlzheimer Diseasephysiology [Nuclear Proteins]medicineAnimalsHumansgenetics [Microtubule Proteins]ddc:610GenePI3K/AKT/mTOR pathwayActivator (genetics)Nuclear Proteinsgenetics [Nuclear Proteins]genetics [Transcription Factors]physiology [Transcription Factors]Ubiquitin ligase030104 developmental biologyHuntington DiseaseMutationbiology.proteinMicrotubule Proteinsphysiology [Microtubule Proteins]CarcinogenesisMid1 protein humanTranscription FactorsFrontiers in bioscience (Landmark edition)
researchProduct

European contribution to the study of ROS : A summary of the findings and prospects for the future from the COST action BM1203 (EU-ROS)

2017

WOS: 000410470000009

0301 basic medicinereactive oxygen species ; reactive nitrogen species ; redox signaling ; oxidative stress ; antioxidants ; redox therapeuticsRedox signalingInternational CooperationSMOOTH-MUSCLE-CELLS[SDV]Life Sciences [q-bio]Clinical BiochemistryISCHEMIA-REPERFUSION INJURYReviewddc:616.07Bioinformaticsmedicine.disease_causeBiochemistryAntioxidants0302 clinical medicineENDOPLASMIC-RETICULUM STRESSCost actionlcsh:QH301-705.5ComputingMilieux_MISCELLANEOUSmedia_commonlcsh:R5-920Redox therapeuticsReactive nitrogen species3. Good healthVariety (cybernetics)MANGANESE SUPEROXIDE-DISMUTASECHRONIC GRANULOMATOUS-DISEASERisk analysis (engineering)ddc:540lcsh:Medicine (General)Oxidation-ReductionSignal TransductionSocieties ScientificPULMONARY ARTERIAL-HYPERTENSIONMedicinaEstrès oxidatiuBiology03 medical and health sciencesAntioxidants ; Oxidative Stress ; Reactive Nitrogen Species ; Reactive Oxygen Species ; Redox Signaling ; Redox TherapeuticsJournal Articlemedicinemedia_common.cataloged_instanceAnimalsHumans[CHIM]Chemical SciencesEuropean UnionEuropean unionNITRIC-OXIDE SYNTHASETANDEM MASS-SPECTROMETRYMolecular BiologyMITOCHONDRIAL OXIDATIVE STRESSGROWTH-FACTOR-BETAOrganic ChemistryDisease progressionBiology and Life SciencesOxidation reductionManganese Superoxide Dismutase030104 developmental biologylcsh:Biology (General)Oxidative stressReactive oxygen species030217 neurology & neurosurgeryOxidative stressRedox biology
researchProduct

Requirements Analysis and Specification for a Molecular Tumor Board Platform Based on cBioPortal

2020

Clinicians in molecular tumor boards (MTB) are confronted with a growing amount of genetic high-throughput sequencing data. Today, at German university hospitals, these data are usually handled in complex spreadsheets from which clinicians have to obtain the necessary information. The aim of this work was to gather a comprehensive list of requirements to be met by cBioPortal to support processes in MTBs according to clinical needs. Therefore, oncology experts at nine German university hospitals were surveyed in two rounds of interviews. To generate an interview guideline a scoping review was conducted. For visual support in the second round, screenshot mockups illustrating the requirements …

0301 basic medicinerequirements analysisdecision making computer-assistedComputer scienceprecision medicineClinical BiochemistrySequencing dataneoplasmsdecision support systems clinicalmolecular tumor boardArticleGerman03 medical and health sciencescomputational biology0302 clinical medicineMedizinische FakultätTumor boardddc:610Requirements analysislcsh:R5-920GuidelinePrecision medicineUniversity hospitallanguage.human_languagecBioPortalEngineering management030104 developmental biologyWork (electrical)030220 oncology & carcinogenesislanguagelcsh:Medicine (General)Diagnostics
researchProduct